London, United Kingdom

Kenneth Dawson Bagshawe


Average Co-Inventor Count = 1.4

ph-index = 5

Forward Citations = 141(Granted Patents)


Location History:

  • London, W.1., GB (1988)
  • London, GB (1997 - 2001)

Company Filing History:


Years Active: 1988-2001

Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovations of Kenneth Dawson Bagshawe

Introduction

Kenneth Dawson Bagshawe is a notable inventor based in London, GB. He has made significant contributions to the field of cytotoxic drug therapy, holding a total of seven patents. His work focuses on developing compounds that enhance the effectiveness of cancer treatments while minimizing damage to normal tissues.

Latest Patents

One of Kenneth's latest patents involves a compound that comprises a target cell-specific portion, such as an antibody specific to tumor cell antigens, and an inactivating portion, such as an enzyme. This enzyme is capable of converting a substance that, in its native state, inhibits the effect of a cytotoxic agent into a substance that has less effect against said cytotoxic agent. This innovation allows for prolonged action of a cytotoxic agent at tumor sites, thereby protecting normal tissues from the adverse effects of the cytotoxic agent.

Career Highlights

Throughout his career, Kenneth has worked with various organizations, including Enzacta R & D Limited and Cancer Research Campaign Technology Limited. His expertise in drug therapy has positioned him as a key figure in the fight against cancer.

Collaborations

Kenneth has collaborated with notable professionals in his field, including Gordon T Rogers and Surinder K Sharma. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Kenneth Dawson Bagshawe's work in cytotoxic drug therapy exemplifies the impact of innovative thinking in medical science. His patents and collaborations continue to pave the way for advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…